Synonyms
- Anti-dense fine speckled
- DFS70/LEDGFp75
- LEDGFp75
- Lens Epithelium-derived Growth Factor or transcription co-activator p75
- SARD exclusion marker
Expected Turnaround Time
7 - 10 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
For more information, please view the literature below.
Antinuclear Antibodies Initial Screening Profiles Flyer
Specimen Requirements
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube; serum from red-top tube; serum from a gel tube; or serum gel tube
Collection
Separate serum from cells within one hour of collection. Transfer to a plastic transport tube before shipping.
Storage Instructions
Refrigerate or freeze.
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Test Details
Use
Anti-DFS70 antibodies may help identify individuals who do not have an ANA-associated Autoimmune Rheumatic Disease (AARD) especially in the absence of significant clinical findings.1 Anti-DFS70 Ab, especially when positive in isolation (i.e. in the absence of AARD-associated autoantibodies), may prevent unnecessary referrals and examinations of ANA-positive individuals.2
Limitations
This test should be used with clinical findings and other autoimmune testing; it cannot be used alone to rule out autoimmune disease.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
Enzyme-linked immunosorbent assay (ELISA)
Additional Information
Anti-DFS70 antibodies target the dense fine speckled protein of 70 kDa which is identical to Lens Epithelium-Derived Growth Factor or transcription co-activator p75 (LEDGFp75). They are detectable in 2% to 22% of healthy individuals and in less than 1% of patients with AARD are of unknown clinical significance.
Footnotes
1. Conrad K, Röber N, Andrade LEC, Mahler M. The Clinical Relevance of Anti-DFS70 Autoantibodies. Clin Rev Allergy Immunol. 2017 Apr;52(2):202-216.27350273
2. Fitch-Rogalsky C, Steber W, Mahler M, et al. Clinical and Serological Features of Patients Referred through a Rheumatology Triage System because of Positive Antinuclear Antibodies. PLoS One. 2014 Apr 4;9(4):e93812.24705829
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 520313 | Anti-DFS70 Ab | 95129-3 | 520314 | Anti-DFS70 Ab | Units | 95129-3 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf